Considering the important role of IL-11/STAT3 signaling pathway in tumor progression and metastasis, therapeutic options using direct STAT3 inhibitors or upstream inhibitors might be used for the treatment of ccRCC in the future. This evidence concerns the gene IL11 and neoplasm.